My Cart [ 0 ]
Home > Proteins & Peptides > A-Z Proteins  > Biotinylated Human PD-1 Protein

Biotinylated Human PD-1 Protein

PDCD1; PD1; CD279; SLEB2; PD-1

Catalog No. Product Name Size List Price (US$) Quantity
BP004987 Biotinylated Human PD-1/PDCD1 Protein with the C-His-Avi Tag 100 ug 500.00
BP004987 Biotinylated Human PD-1/PDCD1 Protein with the C-His-Avi Tag 500 ug 1750.00
BP005587 Biotinylated Human PD-1/PDCD1 Protein with the C-hFc-Avi Tag 100 ug 500.00
BP005587 Biotinylated Human PD-1/PDCD1 Protein with the C-hFc-Avi Tag 500 ug 1750.00
Description

BP004987: Biotinylated Human PD-1/PDCD1 Protein with the C-His-Avi Tag

Source: The recombinant Biotinylated Human PD-1/PDCD1 Protein, (amino acids Leu25-Gln167) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Molecular Weight: The recombinant Biotinylated Human PD-1/PDCD1 protein with the His-Avi tag at the C-terminus has a predicted MW of 18.9 kDa. Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result.
Activity: Immobilized recombinant Biotinylated Human PD-1 protein with the C-His-Avi tag at 1 ug/ml (100 ul/Well) on streptavidin (5 ug/ml) precoated plate. Dose response curve for the recombinant Human PD-L1 protein with the C-hFc Tag with the EC50 of 23.5ng/ml determined by ELISA (QC Test). The affinity constant of 2.356 uM as determined in SPR assay (Biacore T200).
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.
Formulation: Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution: It is recommended to reconstitute the lyophilized recombinant Biotinylated Human PD-1/PDCD1 Protein in sterile H2O to a protein concentration not less than 100 ug/ml. Centrifuge the tube before opening.

BP005587: Biotinylated Human PD-1/PDCD1 Protein with the C-hFc-Avi Tag

Source: The recombinant Biotinylated Human PD-1/PDCD1 Protein, (amino acids Leu25-Gln167) fused with a hFc-Avi tag at the C-terminus, was produced in HEK 293 cells.
Molecular Weight: The recombinant Biotinylated Human PD-1/PDCD1 protein with the hFc-Avi tag at the C-terminus has a predicted MW of 44.7 kDa. Due to glycosylation, the protein migrates to 65-72 kDa based on Bis-Tris PAGE result.
Activity: Immobilized recombinant Human PD-L1 protein with the C-hFc-Avi tag at 2 ug/ml (100 ul/Well). Dose response curve for the recombinant Biotinylated Human PD-1 protein with the C-hFc tag with the EC50 of 0.23 ug/ml determined by ELISA.
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.
Formulation: Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution: It is recommended to reconstitute the lyophilized recombinant Biotinylated Human PD-1/PDCD1 Protein in sterile H2O to a protein concentration not less than 100 ug/ml. Centrifuge the tube before opening.


Shipping: The recombinant Biotinylated Human PD-1/PDCD1 Protein is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 week, 2 to 8°C under sterile conditions after reconstitution.
6 months, -20 to -70°C under sterile conditions after reconstitution.

References of Biotinylated Human PD-1 Protein:


Engineering PD-1-targeted small protein variants for in vitro diagnostics and in vivo PET imaging.
Joanna Maria Mierzwicka et al. J Transl Med. 2024 May 6;22(1):426. doi: 10.1186/s12967-024-05210-x. PMID: 38711085
Programmed cell death 1 (PD-1) belongs to immune checkpoint proteins ensuring negative regulation of the immune response. In non-small cell lung cancer (NSCLC), the sensitivity to treatment with anti-PD-1 therapeutics, and its efficacy, mostly correlated with the increase of tumor infiltrating PD-1+ lymphocytes. Due to solid tumor heterogeneity of PD-1+ populations, novel low molecular weight anti-PD-1 high-affinity diagnostic probes can increase the reliability of expression profiling of PD-1+ tumor infiltrating lymphocytes (TILs) in tumor tissue biopsies and in vivo mapping efficiency using immune-PET imaging. We designed a 13 kDa β-sheet Myomedin scaffold combinatorial library by randomization of 12 mutable residues, and in combination with ribosome display, we identified anti-PD-1 Myomedin variants (MBA ligands) that specifically bound to human and murine PD-1-transfected HEK293T cells and human SUP-T1 cells spontaneously overexpressing cell surface PD-1. Using directed evolution, we developed a unique set of small binding proteins that can improve PD-1 diagnostics in vitro as well as in vivo using PET/CT imaging.
Tags: Human PD-1 Protein; Human PD-1/PDCD1 Protein supplier

The role of PD-1 signaling in health and immune-related diseases.
Ru-Yue Chen et al. Front Immunol. 2023. doi: 10.3389/fimmu.2023.1163633. PMID: 37261359
Programmed cell death 1 receptor (PD-1) and its ligands constitute an inhibitory pathway to mediate the mechanism of immune tolerance and provide immune homeostasis. Significantly, the binding partners of PD-1 and its associated ligands are diverse, which facilitates immunosuppression in cooperation with other immune checkpoint proteins. Accumulating evidence has demonstrated the important immunosuppressive role of the PD-1 axis in the tumor microenvironment and in autoimmune diseases. In addition, PD-1 blockades have been approved to treat various cancers, including solid tumors and hematological malignancies. Here, we provide a comprehensive review of the PD-1 pathway, focusing on the structure and expression of PD-1, programmed cell death 1 ligand 1 (PD-L1), and programmed cell death 1 ligand 2 (PD-L2); the diverse biological functions of PD-1 signaling in health and immune-related diseases (including tumor immunity, autoimmunity, infectious immunity, transplantation immunity, allergy and immune privilege); and immune-related adverse events related to PD-1 and PD-L1 inhibitors.
Tags: Human PD-1 Protein price quote; E. coli expressed Human PD-1/PDCD1 Protein

Identification, binding, and structural characterization of single domain anti-PD-L1 antibodies inhibitory of immune regulatory proteins PD-1 and CD80.
Tara Kang-Pettinger et al. J Biol Chem. 2023 Jan;299(1):102769. doi: 10.1016/j.jbc.2022.102769. PMID: 36470427
Programmed death-ligand 1 (PD-L1) is a key immune regulatory protein that interacts with programmed cell death protein 1 (PD-1), leading to T-cell suppression. Whilst this interaction is key in self-tolerance, cancer cells evade the immune system by overexpressing PD-L1. Inhibition of the PD-1/PD-L1 pathway with standard monoclonal antibodies has proven a highly effective cancer treatment; however, single domain antibodies (VHH) may offer numerous potential benefits. Here, we report the identification and characterization of a diverse panel of 16 novel VHHs specific to PD-L1. The panel of VHHs demonstrate affinities of 0.7 nM to 5.1 μM and were able to completely inhibit PD-1 binding to PD-L1.
Tags: Biotinylated Human PD-1 Protein for cell culture; bulk Human PD-1/PDCD1 Protein

High-potency PD-1/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells.
Dai MY, Shi YY, Wang AJ, Liu XL, Liu M, Cai HB. Cell Death Dis. 2022 Nov 4;13(11):924. doi: 10.1038/s41419-022-05375-7. PMID: 36333311
The AlphaFold 2 Artificial Intelligence system was used to generate three-dimensional structures of Peptide 1 (targeting PD-1) and Peptide 2 (targeting DHHC3, upstream of PD-L1) and visualizations were performed using the PyMOL software. c Western blotting analysis of C33A cells after treatment with the Peptide-PROTAC (Peptide 1 and Peptide 2) degraders at the indicated doses and timepoints. Both Peptide 1 and 6 target for PD-1, but Peptide 1 had a much better degradation effect than Peptide 6. Peptide 2 targeting for PD-L1 palmitoyltransferase ZDHHC3 (DHHC3) had a much better PD-L1 decrease effect than Peptide 11 targeting for PD-L1 directly and Peptide 12 which is the inhibition peptide without EPR sequence. e C33A cells were treated with 10 μM of rhodamine-labeled Peptide-PROTAC targeting PD-1 or PD-L1.
Tags: activity of Biotinylated Human PD-1 Protein; function of Biotinylated Human PD-1 Protein

Revisiting the PD-1 pathway.
Patsoukis N et al. Sci Adv. 2020 Sep 18;6(38):eabd2712. doi: 10.1126/sciadv.abd2712. PMID: 32948597
Programmed Death-1 (PD-1; CD279) is an inhibitory receptor induced in activated T cells. PD-1 engagement by its ligands, PD-L1 and PD-L2, maintains peripheral tolerance but also compromises anti-tumor immunity. Blocking antibodies against PD-1 or its ligands have revolutionized cancer immunotherapy. However, only a fraction of patients develop durable antitumor responses. Clinical outcomes have reached a plateau without substantial advances by combinatorial approaches.
Tags: Biotinylated Human PD-1 Protein dose range; Human PD-1/PDCD1 Protein injection dose

For more references about biotinylated human PD-1 protein please contact our scientific support team with message@sydlabs.com.

Syd Labs also provides the following PD-1/PDCD1 Protein:
Biotinylated Mouse PD-1 Protein
Human PD-1/PDCD1 Protein
Mouse PD-1/PDCD1 Protein
Cynomolgus PD-1/PDCD1 Protein
Canine PD-1/PDCD1 Protein
Human VEGF Protein
Human IL-2 Protein

Syd Labs provides the following anti-mouse PD-L1 / PD-1 antibodies:
In vivo grade recombinant anti-mouse PD1 antibodies (Clone 29F.1A12.1)
In vivo grade recombinant anti-mouse PD-1 antibodies (Clone RMP1-14.1)
In vivo grade recombinant anti-mouse PD-L1 antibodies (Clone 10F.9G2.1)

Syd Labs also provides the following PD-L1/PD-L2 Protein:
Human PD-L1/B7-H1 Protein
Cynomolgus PD-L1/B7-H1 Protein
Mouse PD-L1/B7-H1 Protein
Human PD-L2/B7-DC Protein
Biotinylated Human PD-L1 Protein

Related Links

See our Privacy Policy